Equities Analysts Offer Predictions for Celcuity Q1 Earnings

Celcuity Inc. (NASDAQ:CELC) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Celcuity in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.83) for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. Leerink Partnrs also issued estimates for Celcuity’s Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.77) EPS, FY2026 earnings at ($3.33) EPS and FY2027 earnings at $0.63 EPS.

A number of other research analysts have also recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC boosted their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $30.17.

Celcuity Price Performance

Shares of Celcuity stock opened at $12.10 on Monday. Celcuity has a twelve month low of $10.35 and a twelve month high of $22.19. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a market cap of $449.27 million, a P/E ratio of -4.64 and a beta of 0.73. The firm’s 50-day simple moving average is $12.28 and its 200-day simple moving average is $14.29.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Celcuity during the third quarter valued at $33,000. Prospera Private Wealth LLC bought a new stake in Celcuity during the 3rd quarter worth about $35,000. Values First Advisors Inc. acquired a new position in Celcuity during the 3rd quarter valued at about $86,000. SG Americas Securities LLC bought a new position in shares of Celcuity in the 3rd quarter valued at about $119,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Celcuity during the 4th quarter worth approximately $146,000. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.